> Pfizer is restructuring its operations in France, and you know what that means: streamlining, a.k.a. layoffs. The company said 700 jobs will be cut in the reorganization, with the layoffs focused on its French HQ in Paris and its sales force. Its union, however, claims that the cuts actually will amount to 892. Report
> GlaxoSmithKline won FDA approval for its Boostrix vaccine for adults, designed to protect against tetanus, diptheria, and whooping cough. Report
> EFT BioTech Holdings announced that it has filed Form 10 with the SEC. Report
> Mike Cassidy outlines the need for more support for Georgia's biotech sector after the University of Georgia loses out to Kansas State University for the National Bio- and Agro-Defense Facility (NBAF). Report
> Genta has filed an appeal of the recent negative FDA decision regarding the company's NDA for its lead oncology product, Genasense. Release
> Ablynx announced today that its anti-thrombotic ALX-0081 has reached the primary endpoint of the current Phase Ib study, demonstrating the desired pharmacological effect. Release
> Crucell announced that its monoclonal antibody outperformed the most current anti-influenza drug in preclinical tests. Report
> The European Union's proposed new rules for governing the drug industry could lead the region toward more pharma marketing. Report
> One of the rumored candidates for the top post at FDA--Baltimore Health Department chief Joshua Sharfstein--has been tapped to head up a team charged with assessing the agency. Report
> As usual, when a bunch of doctors get together with a slew of researchers, press releases poured out of the breast cancer symposium in San Antonio this week. Here's a sampling of the news that could affect your favorite drugmakers. Report
> When it came to the vote, the FDA's asthma drugs advisory panel wasn't as evenly split as it seemed. Report
And Finally... At BIOQatar 2008, Qatar announced its intentions to become the Middle East's leading biotech hub. Report